BAX Quote, Financials, Valuation and Earnings

Becton Dickinson & has a net margin of 4.8% compared to Baxter International's net margin of 5.84%. Baxter International's return on equity of -7.38% beat Becton Dickinson &'s return on equity of 5.86%.

Baxter International has a consensus price target of $38.34, signalling upside risk potential of 25.22%. On the other hand Becton Dickinson & has an analysts' consensus of $221.75 which suggests that it could grow by 28.77%. Given that Becton Dickinson & has higher upside potential than Baxter International, analysts believe Becton Dickinson & is more attractive than Baxter International.

Baxter International has a beta of 0.614, which suggesting that the stock is 38.622% less volatile than S&P 500. In comparison Becton Dickinson & has a beta of 0.251, suggesting its less volatile than the S&P 500 by 74.889%.

Baxter International has a quarterly dividend of $0.17 per share corresponding to a yield of 2.61%. Becton Dickinson & offers a yield of 2.36% to investors and pays a quarterly dividend of $1.04 per share. Baxter International pays -90.91% of its earnings as a dividend. Becton Dickinson & pays out 64.52% of its earnings as a dividend. Becton Dickinson &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Baxter International quarterly revenues are $2.6B, which are smaller than Becton Dickinson & quarterly revenues of $5.3B. Baxter International's net income of $126M is lower than Becton Dickinson &'s net income of $308M. Notably, Baxter International's price-to-earnings ratio is 167.20x while Becton Dickinson &'s PE ratio is 32.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Baxter International is 1.32x versus 2.39x for Becton Dickinson &. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific has a net margin of 4.8% compared to Baxter International's net margin of 14.45%. Baxter International's return on equity of -7.38% beat Boston Scientific's return on equity of 9.57%.

Baxter International has a consensus price target of $38.34, signalling upside risk potential of 25.22%. On the other hand Boston Scientific has an analysts' consensus of $117.02 which suggests that it could grow by 17.33%. Given that Baxter International has higher upside potential than Boston Scientific, analysts believe Baxter International is more attractive than Boston Scientific.

Baxter International has a beta of 0.614, which suggesting that the stock is 38.622% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.681, suggesting its less volatile than the S&P 500 by 31.908%.

Baxter International has a quarterly dividend of $0.17 per share corresponding to a yield of 2.61%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Baxter International pays -90.91% of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.

Baxter International quarterly revenues are $2.6B, which are smaller than Boston Scientific quarterly revenues of $4.7B. Baxter International's net income of $126M is lower than Boston Scientific's net income of $674M. Notably, Baxter International's price-to-earnings ratio is 167.20x while Boston Scientific's PE ratio is 72.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Baxter International is 1.32x versus 8.46x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of 4.8% compared to Baxter International's net margin of 6.22%. Baxter International's return on equity of -7.38% beat Insulet's return on equity of 36.9%.

Baxter International has a consensus price target of $38.34, signalling upside risk potential of 25.22%. On the other hand Insulet has an analysts' consensus of $334.74 which suggests that it could grow by 9.89%. Given that Baxter International has higher upside potential than Insulet, analysts believe Baxter International is more attractive than Insulet.

Baxter International has a beta of 0.614, which suggesting that the stock is 38.622% less volatile than S&P 500. In comparison Insulet has a beta of 1.375, suggesting its more volatile than the S&P 500 by 37.475%.

Baxter International has a quarterly dividend of $0.17 per share corresponding to a yield of 2.61%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Baxter International pays -90.91% of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

Baxter International quarterly revenues are $2.6B, which are larger than Insulet quarterly revenues of $569M. Baxter International's net income of $126M is higher than Insulet's net income of $35.4M. Notably, Baxter International's price-to-earnings ratio is 167.20x while Insulet's PE ratio is 54.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Baxter International is 1.32x versus 10.25x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

Stryker has a net margin of 4.8% compared to Baxter International's net margin of 11.15%. Baxter International's return on equity of -7.38% beat Stryker's return on equity of 14.2%.

Baxter International has a consensus price target of $38.34, signalling upside risk potential of 25.22%. On the other hand Stryker has an analysts' consensus of $421.46 which suggests that it could grow by 11.7%. Given that Baxter International has higher upside potential than Stryker, analysts believe Baxter International is more attractive than Stryker.

Baxter International has a beta of 0.614, which suggesting that the stock is 38.622% less volatile than S&P 500. In comparison Stryker has a beta of 0.914, suggesting its less volatile than the S&P 500 by 8.615%.

Baxter International has a quarterly dividend of $0.17 per share corresponding to a yield of 2.61%. Stryker offers a yield of 0.87% to investors and pays a quarterly dividend of $0.84 per share. Baxter International pays -90.91% of its earnings as a dividend. Stryker pays out 40.73% of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Baxter International quarterly revenues are $2.6B, which are smaller than Stryker quarterly revenues of $5.9B. Baxter International's net income of $126M is lower than Stryker's net income of $654M. Notably, Baxter International's price-to-earnings ratio is 167.20x while Stryker's PE ratio is 50.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Baxter International is 1.32x versus 6.27x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.